Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Top Cited Papers
- 1 March 2002
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 359 (9311), 995-1003
- https://doi.org/10.1016/s0140-6736(02)08089-3
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Stroke is More Common than Myocardial Infarction in Hypertension: Analysis based on 11 Major Randomized Intervention TrialsBlood Pressure, 2001
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Characteristics of 9194 Patients With Left Ventricular HypertrophyHypertension, 1998
- Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trialsJournal Of Hypertension, 1996
- Electrocardiographic identification of left ventricular hypertrophy: Test performance in relation to definition of hypertrophy and presence of obesityJournal of the American College of Cardiology, 1996
- Electrocardiographic identification of increased left ventricular mass by simple voltage-duration productsJournal of the American College of Cardiology, 1995
- Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)The Lancet, 1991
- Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trialsThe American Journal of Cardiology, 1986
- Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial InfarctionNew England Journal of Medicine, 1981